SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001493152-23-030659
Filing Date
2023-08-30
Accepted
2023-08-30 16:05:19
Documents
18
Period of Report
2023-08-29
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 form8-k.htm   iXBRL 8-K 45231
2 ex4-1.htm EX-4.1 115031
3 ex5-1.htm EX-5.1 20017
4 ex10-1.htm EX-10.1 241908
5 ex99-1.htm EX-99.1 17992
6 ex5-1_001.jpg GRAPHIC 2389
7 ex99-1_001.jpg GRAPHIC 13675
  Complete submission text file 0001493152-23-030659.txt   731238

Data Files

Seq Description Document Type Size
8 XBRL SCHEMA FILE dare-20230829.xsd EX-101.SCH 3033
9 XBRL LABEL FILE dare-20230829_lab.xml EX-101.LAB 34916
10 XBRL PRESENTATION FILE dare-20230829_pre.xml EX-101.PRE 22801
12 EXTRACTED XBRL INSTANCE DOCUMENT form8-k_htm.xml XML 3437
Mailing Address 3655 NOBEL DRIVE SUITE 260 SAN DIEGO CA 92122
Business Address 3655 NOBEL DRIVE SUITE 260 SAN DIEGO CA 92122 858-926-7655
Dare Bioscience, Inc. (Filer) CIK: 0001401914 (see all company filings)

IRS No.: 204139823 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36395 | Film No.: 231225279
SIC: 2834 Pharmaceutical Preparations